07 December 2018
In a new study, Tel Aviv University (Israel) researchers reveal how they invented the first fully personalized tissue implant, engineered from a patient’s own materials and cells. The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.
The research, conducted by Prof. Reuven Edri, was recently published in scientific journal ‘Advanced Materials’. Currently, in tissue engineering for regenerative medicine, cells are isolated from the patient and cultured in biomaterials to assemble into a functional tissue. These biomaterials are always either synthetic or natural, derived from plants or animals. After transplantation, they may induce an immune response that leads to rejection of the implanted tissue. Patients receiving engineered tissues or any other implants are treated with immuno-suppressors, which themselves endanger the health of the patient.
The researchers extracted a small biopsy of fatty tissue from patients, then separated its cellular and a-cellular materials. While the cells were reprogrammed to become induced pluripotent stem cells – able to make cells from all three basic body layers, so they can potentially produce any cell or tissue the body needs to repair itself — the extracellular material was processed to become a personalized hydrogel. After combining the resulting stem cells and the hydrogel, the scientists successfully engineered the personalized tissue samples and tested the patients’ immune responses to them.
The scientists are currently engaged in regenerating an injured spinal cord and an infarcted heart with spinal cord and cardiac implants. They have also begun to investigate the potential of human dopaminergic implants to treat Parkinson’s disease in animal models. The researchers plan to regenerate other organs, including intestines and eyes, using the patients’ own materials and cells.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024